March 22, 2026 a 01:00 pm
ISRG: Analysts Ratings - Intuitive Surgical, Inc.
Intuitive Surgical, Inc. remains a pivotal player in the evolution of minimally invasive care, bolstered by its da Vinci Surgical System. Recent analyst ratings reflect ongoing interest and favorable sentiment towards the stock, highlighted by a diversified recommendation landscape. This provides a well-rounded perspective on its positioning within the healthcare technology sector.
Historical Stock Grades
An analysis of the recent ratings for Intuitive Surgical, Inc. showcases ongoing confidence in the company's market position. The current rating configuration, as of March 2026, reveals a predominant inclination towards bullish expectations.
| Rating | Number of Recommendations | Score Visual |
|---|---|---|
| Strong Buy | 8 | |
| Buy | 17 | |
| Hold | 10 | |
| Sell | 1 | |
| Strong Sell | 1 |
Sentiment Development
The sentiment trajectory for Intuitive Surgical over the past months reveals strategic shifts in analyst perspectives. Significant observations include:
- The total number of ratings has remained relatively stable, with minor fluctuations in category orientations.
- Buy recommendations have seen a slight increase, resonating with increased investor confidence in future growth.
- Hold ratings exhibit variability, indicating indecision or market anticipations related to upcoming industry pressures.
Percentage Trends
Evaluation of the percentage distribution of ratings over time indicates notable shifts:
- The proportion of Strong Buy ratings has decreased marginally over the past months, suggesting a cautious approach by analysts.
- Hold ratings maintained a consistent presence, highlighting ongoing market uncertainties or valuation concerns.
- Strong Sell and Sell ratings remain minimal, demonstrating robust fundamental belief in Intuitive Surgical's potential.
- Prominent changes over the last year encompass a transition from Strong Buy to more conservative Buy and Hold recommendations.
Latest Analyst Recommendations
Recent recommendations for Intuitive Surgical indicate strategic insights and market forecasts.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-03-17 | Neutral | Neutral | UBS |
| 2026-03-11 | Buy | Neutral | Citigroup |
| 2026-02-24 | Neutral | Neutral | UBS |
| 2026-01-27 | Buy | Hold | Freedom Capital Markets |
| 2026-01-26 | Overweight | Overweight | Barclays |
Analyst Recommendations with Change of Opinion
Recent changes in ratings reflect analysts' evolving perspectives on Intuitive Surgical.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-03-11 | Buy | Neutral | Citigroup |
| 2026-01-27 | Buy | Hold | Freedom Capital Markets |
| 2025-12-11 | Neutral | Buy | Citigroup |
| 2025-06-09 | Sell | Hold | Deutsche Bank |
| 2024-12-02 | Overweight | Equal Weight | Morgan Stanley |
Interpretation
The current analyst sentiment towards Intuitive Surgical suggests a balanced market outlook, characterized by sustained interest in its technological advancements. The preponderance of Buy and Hold ratings indicates a cautious optimism, while occasional alterations reflect sector-specific volatility and strategic reevaluations. Despite moderate fluctuations, the steadiness in ratings implies enduring confidence among stakeholders.
Conclusion
Intuitive Surgical continues to be a prominent and influential entity within the medical technology space, represented by analyst recommendations that convey both opportunities and risks. The observable trends indicate a firm belief in the company’s prospects, albeit with cautious approaches to forthcoming challenges. The dedication to minimally invasive solutions and cutting-edge systems supports its long-term potential, making the stock appealing to strategic investors.
Smart Data Insight
Master the Perfect Entry & Exit for this Stock
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.
- ✅ Identify the "Golden Buying Window"
- ✅ Avoid high-risk correction cycles
- ✅ Backtested data from the last 20+ years